Cargando…
Regression of Stage IV Pancreatic Cancer to Curative Surgery and Introduction of a Novel Ex-Vivo Chemosensitivity Assay
Although data suggests little hope for survival when patients present with metastatic pancreatic cancer, recent advances in systemic therapy offer the possibility for dramatic tumor responses like those observed in other disease sites. Here, we present the case of a 50-year-old woman who presented w...
Autores principales: | Rios Perez, Mayrim V, Dai, Bingbing, Koay, Eugene J, Wolff, Robert A, Fleming, Jason B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727941/ https://www.ncbi.nlm.nih.gov/pubmed/26848412 http://dx.doi.org/10.7759/cureus.423 |
Ejemplares similares
-
Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma
por: Kim, Dae Won, et al.
Publicado: (2023) -
Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladder
por: van den Tempel, Nathalie, et al.
Publicado: (2018) -
Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models
por: Rios Perez, Mayrim V., et al.
Publicado: (2019) -
Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer
por: Michalski, C W, et al.
Publicado: (2008) -
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia
por: Megías-Vericat, Juan Eduardo, et al.
Publicado: (2019)